Commentary on "Therapy-resistant arterial hypertension: endothelin antagonist aprocitentan convinces"

被引：0

作者：

Duesing, Rainer ^{[1
]}

机构：

[1] Schwerpunktpraxis Kardiol Angiol Pravent Rehabil, Burgweiher 52, D-53123 Bonn, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2023年 / 148卷 / 11期

关键词：

D O I：

10.1055/a-1996-6002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：663 / 663

页数：1

共 5 条

[1]

[Anonymous], 2012, PRNewswire

[2] Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension [J].

Freeman, Mason W. W. ;

Halvorsen, Yuan-Di ;

Marshall, William ;

Pater, Mackenzie ;

Isaacsohn, Jon ;

Pearce, Catherine ;

Murphy, Brian ;

Alp, Nicholas ;

Srivastava, Ajay ;

Bhatt, Deepak L. L. ;

Brown, Morris J. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (05) :395-405

[3] Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial [J].

Schlaich, Markus P. ;

Bellet, Marc ;

Weber, Michael A. ;

Danaietash, Parisa ;

Bakris, George L. ;

Flack, John M. ;

Dreier, Roland F. ;

Sassi-Sayadi, Mouna ;

Haskell, Lloyd P. ;

Narkiewicz, Krzysztof ;

Wang, Ji-Guang .

LANCET, 2022, 400 (10367) :1927-1937

[4] Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension [J].

Verweij, Pierre ;

Danaietash, Parisa ;

Flamion, Bruno ;

Menard, Joel ;

Bellet, Marc .

HYPERTENSION, 2020, 75 (04) :956-965

[5] Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial [J].

Williams, Bryan ;

MacDonald, Thomas M. ;

Morant, Steve ;

Webb, David J. ;

Sever, Peter ;

McInnes, Gordon ;

Ford, Ian ;

Cruickshank, J. Kennedy ;

Caulfield, Mark J. ;

Salsbury, Jackie ;

Mackenzie, Isla ;

Padmanabhan, Sandosh ;

Brown, Morris J. .

LANCET, 2015, 386 (10008) :2059-2068

← 1 →